COMMUNIQUÉS West-GlobeNewswire

Immutep Quarterly Activities Report Q4 FY25
30/07/2025
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and [...]
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
30/07/2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
30/07/2025
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI [...]
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
30/07/2025
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, [...]
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
30/07/2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models
30/07/2025
-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8 th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency [...]
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
30/07/2025
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation [...]
Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy
30/07/2025
BERKELEY, Calif, July 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the [...]
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
30/07/2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R&D [...]
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
30/07/2025
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for cancer FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE [...]
Bionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium
30/07/2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) recently participated in the European Cytogenomics Conference, which is the biennial meeting of the European Cytogenomics Association ( [...]
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
30/07/2025
Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve ® over 6–12 weeks Preclinical in vitro studies demonstrated [...]
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
30/07/2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately [...]
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
30/07/2025
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data [...]
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
30/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
30/07/2025
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer [...]
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
30/07/2025
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) [...]
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
30/07/2025
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed [...]
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
30/07/2025
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company [...]

Pages